Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 489

Sort by

Sort Order Select

Journal Articles

Sensitive, rapid diagnostic test for transient abnormal myelopoiesis and myeloid leukemia of Down syndrome

David Cruz Hernandez, Marlen Metzner, Anne Pieta de Groot, Batchimeg Usukhbayar, Natalina Elliott, Irene Roberts, Paresh Vyas

Blood (2020) 136 (12): 1460–1465.

https://doi.org/10.1182/blood.2020005610

Published: 2020

Includes: Supplemental data

Journal Articles

Minimal Residual Disease and IKZF1 As Predictors of Relapse, and Increased Treatment Related Mortality in Down Syndrome Acute Lymphoblastic Leukemia: A Unique and Large International Matched Case-Control Study

Naomi Michels, BSc, Judith M. Boer, PhD, Marta Lopez-Yurda, PhD, Hester A. De Groot-Kruseman, PhD, Vincent van der Velden, PhD, Anthony V. Moorman, Amir Enshaei, PhD, Ajay Vora, Rosemary Sutton, BSc MSc PhD, Toby Trahair, PhD, Luciano Dalla-Pozza, MBBS FRACP, Rob Pieters, MDPhDMSc, Michel C Zwaan, MD PhD, Monique L. Den Boer, PhD

Blood (2019) 134 (Supplement_1): 827.

https://doi.org/10.1182/blood-2019-124290

Published: 2019

Journal Articles

Increased Mutagenesis during Fetal Hematopoietic Development in Down Syndrome

Karlijn Hasaart, MSc, Freek Manders, MSc, Susana Chuva de Sousa Lopes, PhD, Ruben Van Boxtel, PhD

Blood (2019) 134 (Supplement_1): 1186.

https://doi.org/10.1182/blood-2019-122855

Published: 2019

Journal Articles

Delays in Therapy Do Not Impact Survival in Childhood Acute Lymphoblastic Leukemia: A Report from the Learn Consortium

Ross Mangum, MD, Tiffany M. Chambers, MPH, Andria Stevens, MPH, Robert C. Lynch, MD, Evanette Burrows, MPH, Tamara P. Miller, MDMSc, Kelly D Getz, Richard Aplenc, MD PhD, Philip J. Lupo, PhD MPH, Maria Monica J. Gramatges, MD PhD, Michael E. Scheurer, PhD MPH, Karen R. Rabin, MD PhD

Blood (2019) 134 (Supplement_1): 1304.

https://doi.org/10.1182/blood-2019-130351

Published: 2019

Journal Articles

Successful Toxicity Reduction in Ma-Spore ALL 2010 in Standard/Intermediate Risk Childhood ALL: Replacing Cytarabine/Doxorubicin with More Vincristine and L-Asparaginase during Consolidation and Delayed Intensification

Bernice Oh, MBBS, MRCP, Shawn Lee, MD, Zelia Seeto, Germaine Liew, Bsc, Edwynn Chiew, MBBS, Zhi Wei Chen, Bsc, Yiong Huak Chan, PhD, Jing Jia Eng, Bsc, Koon Mian Foo, Bsc, Ching Mei Joyce Lam, MD, Ah Moy Tan, MD, Allen Eng Juh Yeoh, MD

Blood (2019) 134 (Supplement_1): 1307.

https://doi.org/10.1182/blood-2019-122098

Published: 2019

Journal Articles

The Clinical Application of Oncomine Myeloid Next Generation Sequencing (NGS): Comparison of Cytogenetics and NGS in Patients with Suspected Myelodysplastic Syndrome

Eri Kawata, MD PhD, Anargyros Xenocostas, MD FRCPC, Cyrus C. Hsia, MDBSc,FRCPC, Uday Deotare, MBBS, MD DM, Lalit Saini, MD, Ping Yang, PhD DABMGG, Michael Levy, PhD, Hanxin Lin, PhD, Bekim Sadikovic, PhD DABMGG, FACMG, Ian Chin-Yee, MD FRCPC

Blood (2019) 134 (Supplement_1): 3375.

https://doi.org/10.1182/blood-2019-126893

Published: 2019

Journal Articles

The Genome-Wide Impact of Trisomy 21 on DNA Methylation and Its Implications for Hematologic Malignancies

Joseph L. Wiemels, PhD, Ivo S Muskens, Shaobo Li, Priyatama Pandey, Ritu Roy, PhD, Helen M Hansen, BSc, Kimberly D Siegmund, PhD, Beth A Mueller, PhD, Xiaomei Ma, PhD, Catherine Metayer, MD PhD, Adam J de Smith, PhD

Blood (2019) 134 (Supplement_1): 2510.

https://doi.org/10.1182/blood-2019-131455

Published: 2019

Journal Articles

Area-Based Socioeconomic Disparities in Survival of Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Lena E. Winestone, MD, Kelly D Getz, Kira O Bona, MDMPH, Brian T. Fisher, DO, MSCE, Alan S Gamis, MD MPH, Alix E. Seif, MD, Lillian Sung, MD PhD, Yi-Cheng Wang, Todd A. Alonzo, PhD, Richard Aplenc, MD PhD

Blood (2019) 134 (Supplement_1): 703.

https://doi.org/10.1182/blood-2019-130978

Published: 2019

Journal Articles

Impact of a Risk-Adapted Treatment Approach in Pediatric AML: A Report of the AML-BFM Registry 2012

Mareike Rasche, MD, Emma Steidel, Denise Kondryn, Nils Von Neuhoff, PhD, Lucie Sramkova, MD, Ursula Creutzig, MD, Michael Dworzak, MD, Dirk Reinhardt, MD

Blood (2019) 134 (Supplement_1): 293.

https://doi.org/10.1182/blood-2019-130969

Published: 2019

Journal Articles

High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction

Johann K. Hitzler, MD, Jason Berman, MD, Robert B. Gerbing, Amy Beckman, Betsy A Hirsch, PhD, Susana C. Raimondi, PhD, Todd E Druley, MD PhD, Michael R. Loken, PhD, Lisa Eidenschink Brodersen, PhD, Karen Chisholm, Shelton A. Viola, MD, Jeffrey W. Taub, MD, Alan S Gamis, MD MPH, Todd A. Alonzo, PhD, E. Anders Kolb, MD

Blood (2019) 134 (Supplement_1): 118.

https://doi.org/10.1182/blood-2019-126723

Published: 2019

Journal Articles

Predictive Factors of the Development of Leukemia in Patients with Transient Abnormal Myelopoiesis and Down Syndrome: The Jccg Study JPLSG TAM-10

Blood (2019) 134 (Supplement_1): 3833.

https://doi.org/10.1182/blood-2019-125465

Published: 2019

Journal Articles

Phase II Study of Midostaurin + Chemotherapy in Pediatric Patients with Untreated, Newly Diagnosed, FLT3 -Mutated Acute Myeloid Leukemia (AML)

Dirk Reinhardt, MD, Christian Michel Zwaan, Albert Hoenekopp, Julie Niolat, Sophie Ifrah, Florence Noel-Baron, Franco Locatelli, MD

Blood (2019) 134 (Supplement_1): 3835.

https://doi.org/10.1182/blood-2019-128043

Published: 2019

Journal Articles

Post-Induction Minimal Residual Disease Measured By Flow Cytometry and Deep Sequencing of Mutant GATA1 Are Both Significant Prognostic Factors for Children with Myeloid Leukemia and Down Syndrome: A Nationwide Prospective Study of the Japanese Pediatric Leukemia/Lymphoma Study Group

Blood (2019) 134 (Supplement_1): 3848.

https://doi.org/10.1182/blood-2019-123302

Published: 2019

Journal Articles

CBFA2T3-GLIS2 Fusion Gene Cause Dismal Clinical Course in Acute Megakaryocytic Leukemia of Down Syndrome

Nao Takasugi, Kenichi Amano, Yasuo Kubota, MD, Shota Kato, MD, Yuichi Mitani, MD, Junya Fujimura, MD PhD, Junko Takita, MD PhD, Mitsuteru Hiwatari, MD PhD

Blood (2019) 134 (Supplement_1): 5184.

https://doi.org/10.1182/blood-2019-129165

Published: 2019

Journal Articles

Spatio-Temporal Clustering of Childhood Leukemia Relative to Population Mixing in Finland: A Nationwide Register-Based Study

Atte Nikkilä, MD, Jani Raitanen, MSc, Olli Lohi, MD PhD, Anssi Auvinen, MD PhD

Blood (2019) 134 (Supplement_1): 5070.

https://doi.org/10.1182/blood-2019-125930

Published: 2019

Journal Articles

Improved Treatment of Childhood ALL in Malaysia

Hamidah Alias, MMed (Paed), Sie Chong Doris Lau, MMed (Paed), C-Khai Loh, MRCPCH, Christine J. Harrison, PhD FRCPath, Jeyanthy Eswaran, PhD

Blood (2019) 134 (Supplement_1): 5828.

https://doi.org/10.1182/blood-2019-129402

Published: 2019

Journal Articles

The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia

Kathryn G. Roberts, PhD, Samuel W. Brady, PhD, Zhaohui Gu, PhD, Lei Shi, PhD, Stanley Pounds, PhD, Deqing Pei, MS, Cheng Cheng, PhD, Yunfeng Dai, PhD, Meenakshi Devidas, PhD, Chunxu Qu, PhD, Ashley Hill, BS, Xiaotu Ma, Lei Wei, PhD, Sasi Arunachalam, PhD, Kohei Hagiwara, MD, Yangling Liu, Diane Flasch, Yu Liu, PhD, Matthew Parker, PhD, Xiaolong Chen, PhD, Yongjin Li, PhD, Yiping Fan, PhD, Robert Michael, PhD, Michael Rusch, BS, Mark Wilkinson, Scott Foy, PhD, Dale Hedges, PhD, Scott Newman, PhD, Xin Zhou, PhD, Jian Wang, Shalini C. Reshmi, PhD, Julie M. Gastier-Foster, PhD, Patee Gesuwan, Malcolm A Smith, MD PhD, Daniela S. Gerhard, PhD, Naomi Winick, MD, Andrew J. Carroll, PhD, Nyla A. Heerema, PhD, Richard C. Harvey, PhD, Cheryl L. Willman, MD, Eric Larsen, MD, Elizabeth A. Raetz, MD, Michael J. Borowitz, MD PhD, Brent L Wood, MD PhD, William L. Carroll, MD, Patrick A. Zweidler-McKay, MD PhD, Karen R. Rabin, MD PhD, Leonard A. Mattano, MD, Kelly Maloney, MD, Stuart S. Winter, MD, Michael J. Burke, MD, Wanda L. Salzer, MD, Kimberly P. Dunsmore, Anne Angiolillo, MD, Kristine R Crews, PharmD, James R. Downing, MD, Sima Jeha, MD, William E. Evans, PharmD, Ching-Hon Pui, MD, Jun J. Yang, PhD, Mary V. Relling, PharmD, Stephen P. Hunger, MD, Mignon L. Loh, MD, Jinghui Zhang, PhD, Charles G. Mullighan, MBBS, MD

Blood (2019) 134 (Supplement_1): 649.

https://doi.org/10.1182/blood-2019-124881

Published: 2019

Journal Articles

Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor and Molecularly Resistant Acute Lymphoblastic Leukemia (R/R ALL): Updated Analysis of 110 Patients Treated in an Expanded Access Study (RIALTO)

Franco Locatelli, MD, Gerhard Zugmaier, Peter Bader, MD, Sima Jeha, MD, Paul-Gerhardt Schlegel, Jean-Pierre Bourquin, MD PhD, Rupert Handgretinger, MD, Benoit Brethon, MD, Claudia Rossig, Christiane Chen-Santel

Blood (2019) 134 (Supplement_1): 1294.

https://doi.org/10.1182/blood-2019-121615

Published: 2019

Journal Articles

Trisomy 21 Driven Pro-Inflammatory Signalling in Fetal Bone Marrow May Play a Role in Perturbed B-Lymphopoiesis and Acute Lymphoblastic Leukemia of Down Syndrome

Sorcha Isabella O'Byrne, BSc, Natalina Elliott, PhD, Gemma Buck, BSc, Siobhan Rice, David O'Connor, Jana Oswald, Hannah Fuchs, Ella-Mae Labbett, Nicholas James Fordham, MBBS, BSc, Anindita Roy, MD PhD, Irene Roberts

Blood (2019) 134 (Supplement_1): 1206.

https://doi.org/10.1182/blood-2019-130180

Published: 2019

Journal Articles

Major Deviations in the Delivery of Induction Chemotherapy Are Associated with an Increased Risk of Relapse in Acute Lymphoblastic Leukaemia: Results from UKALL2003

Rachael E Hough, MD, Amy A Kirkwood, Sujith Samarasinghe, Clare J Rowntree, MBBS, PhD FRCP, FRCPath, Nicholas John Goulden, MD PhD MRCPath, Ajay Vora

Blood (2019) 134 (Supplement_1): 2579.

https://doi.org/10.1182/blood-2019-127223

Published: 2019

NARROW

Sensitive, rapid diagnostic test for transient abnormal myelopoiesis and myeloid leukemia of Down syndrome

Minimal Residual Disease and IKZF1 As Predictors of Relapse, and Increased Treatment Related Mortality in Down Syndrome Acute Lymphoblastic Leukemia: A Unique and Large International Matched Case-Control Study

Increased Mutagenesis during Fetal Hematopoietic Development in Down Syndrome

Delays in Therapy Do Not Impact Survival in Childhood Acute Lymphoblastic Leukemia: A Report from the Learn Consortium

Successful Toxicity Reduction in Ma-Spore ALL 2010 in Standard/Intermediate Risk Childhood ALL: Replacing Cytarabine/Doxorubicin with More Vincristine and L-Asparaginase during Consolidation and Delayed Intensification

The Clinical Application of Oncomine Myeloid Next Generation Sequencing (NGS): Comparison of Cytogenetics and NGS in Patients with Suspected Myelodysplastic Syndrome

The Genome-Wide Impact of Trisomy 21 on DNA Methylation and Its Implications for Hematologic Malignancies

Area-Based Socioeconomic Disparities in Survival of Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Impact of a Risk-Adapted Treatment Approach in Pediatric AML: A Report of the AML-BFM Registry 2012

High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction

Predictive Factors of the Development of Leukemia in Patients with Transient Abnormal Myelopoiesis and Down Syndrome: The Jccg Study JPLSG TAM-10

Phase II Study of Midostaurin + Chemotherapy in Pediatric Patients with Untreated, Newly Diagnosed, FLT3 -Mutated Acute Myeloid Leukemia (AML)

Post-Induction Minimal Residual Disease Measured By Flow Cytometry and Deep Sequencing of Mutant GATA1 Are Both Significant Prognostic Factors for Children with Myeloid Leukemia and Down Syndrome: A Nationwide Prospective Study of the Japanese Pediatric Leukemia/Lymphoma Study Group

CBFA2T3-GLIS2 Fusion Gene Cause Dismal Clinical Course in Acute Megakaryocytic Leukemia of Down Syndrome

Spatio-Temporal Clustering of Childhood Leukemia Relative to Population Mixing in Finland: A Nationwide Register-Based Study

Improved Treatment of Childhood ALL in Malaysia

The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia

Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor and Molecularly Resistant Acute Lymphoblastic Leukemia (R/R ALL): Updated Analysis of 110 Patients Treated in an Expanded Access Study (RIALTO)

Trisomy 21 Driven Pro-Inflammatory Signalling in Fetal Bone Marrow May Play a Role in Perturbed B-Lymphopoiesis and Acute Lymphoblastic Leukemia of Down Syndrome

Major Deviations in the Delivery of Induction Chemotherapy Are Associated with an Increased Risk of Relapse in Acute Lymphoblastic Leukaemia: Results from UKALL2003

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only